ID: ALA3687977

Max Phase: Preclinical

Molecular Formula: C21H21F4N7O2

Molecular Weight: 479.44

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN1C(=O)Cn2c1nc1nc(N3CCC[C@@H](N)C3)n(Cc3cc(F)ccc3C(F)(F)F)c1c2=O

Standard InChI:  InChI=1S/C21H21F4N7O2/c1-29-15(33)10-32-18(34)16-17(27-19(29)32)28-20(30-6-2-3-13(26)9-30)31(16)8-11-7-12(22)4-5-14(11)21(23,24)25/h4-5,7,13H,2-3,6,8-10,26H2,1H3/t13-/m1/s1

Standard InChI Key:  OICPOZZKXXBDTD-CYBMUJFWSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 479.44

Molecular Weight (Monoisotopic): 479.1693

AlogP: 1.70

#Rotatable Bonds: 3

Polar Surface Area: 102.28

Molecular Species: BASE

HBA: 8

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.49

CX Basic pKa: 10.10

CX LogP: 1.71

CX LogD: 0.04

Aromatic Rings: 3

Heavy Atoms: 34

QED Weighted: 0.57

Np Likeness Score: -1.13

References

1.  (2015)  Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors, 

2. Wu WL, Hao J, Domalski M, Burnett DA, Pissarnitski D, Zhao Z, Stamford A, Scapin G, Gao YD, Soriano A, Kelly TM, Yao Z, Powles MA, Chen S, Mei H, Hwa J..  (2016)  Discovery of Novel Tricyclic Heterocycles as Potent and Selective DPP-4 Inhibitors for the Treatment of Type 2 Diabetes.,  7  (5): [PMID:27190600] [10.1021/acsmedchemlett.6b00027]

Source

Source(2):

• Scientific Literature
• BindingDB Database